SCHEMBL7183739

SCHEMBL7183739

COc1cc(OC)c(PC(=O)c2c(Cl)cccc2OC)c(OC)c1.[LiH]

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 1/20 0.44
AURKA O14965 1/20 0.43
ABCG2 Q9UNQ0 4/20 0.43
CA12 O43570 1/20 0.42
CA1 P00915 1/20 0.42
CA2 P00918 1/20 0.42
CA7 P43166 1/20 0.42
CA9 Q16790 1/20 0.42
CA14 Q9ULX7 1/20 0.42
ELANE P08246 1/20 0.42
CXCL12 P48061 1/20 0.40
FABP4 P15090 1/20 0.39
KMT2A Q03164 2/20 0.38
PTGS2 P35354 2/20 0.38
LMNA P02545 1/20 0.38
TAS1R3 Q7RTX0 1/20 0.38
TAS1R1 Q7RTX1 1/20 0.38
TAS1R2 Q8TE23 1/20 0.38
USP2 O75604 1/20 0.38
CYP3A4 P08684 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7185394 0.97 ABCG2 (0.44) MAPTAURKAABCG2ELANECXCL12
SCHEMBL7187593 0.91 MAPT (0.48) MAPTAURKAABCG2CA12CA1
SCHEMBL7182702 0.91 ABCG2 (0.40) MAPTABCG2ELANECXCL12KMT2A
SCHEMBL7188721 0.86 CA12 (0.38) MAPTAURKAABCG2CA12CA1
SCHEMBL7179656 0.85 TTR (0.41) MAPTCA12CA1CA2CA7
SCHEMBL7175820 0.85 BRPF1 (0.39) MAPTCA12CA1CA2CA7
SCHEMBL7189482 0.85 SMN1; SMN2 (0.45) MAPTCA12CA1CA2CA7
SCHEMBL7180839 0.84 CA12 (0.36) MAPTAURKAABCG2CA12CA1
SCHEMBL7181242 0.84 MAPT (0.48) MAPTAURKAABCG2CA12CA1
SCHEMBL7180843 0.83 L3MBTL1 (0.42) MAPTCA12CA1CA2CA7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6579663-B2 Chemical intermediates such as lithium 2,6-dimethylbenzoyl phenylphosphine for preparation of acylphosphines, acylphosphine oxides or acylphosphine sulfides CIBA SPECIALTY CHEMICALS CORPORATION 2003-06-17 US disclosed
US-20020107413-A1 Organometallic monoacylarylphosphines WOLF JEAN-PIERRE (CH) 2002-08-08 US disclosed
US-6399805-B2 SUCH AS LITHIUM 2,6-DIMETHYLBENZOYLPHENYLPHOSPHINE, USE AS PHOTOINITIATORS IN PHOTOCURABLE COMPOSITIONS SUCH AS FOR PHOTOGRAPHIC PRODUCTION OF RELIEF IMAGES CIBA SPECIALTY CHEMICALS CORPORATION 2002-06-04 US disclosed
US-20010031898-A1 Organometallic monoacylarylphosphines CIBA SPECIALTY CHEMICALS CORP. 2001-10-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107413-A1 Organometallic monoacylarylphosphines CBR1, NAF1, DHCR24 MAPT 4870/4885AURKA 2167/4885ABCG2 3732/4885
US-20010031898-A1 Organometallic monoacylarylphosphines NAF1, DHCR24, CBR1 MAPT 4859/4885AURKA 2395/4885ABCG2 4323/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.